Diabetic Macular Edema
Conditions
Brief summary
This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.
Detailed description
At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was injected into subconjunctival space of the eyes with diabetic macular edema. The measurements of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th day after injections. The macular thickness measurements before and after injection were compared.
Interventions
DRUGSubconjunctival bevacizumab (Altuzan)
Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
Sponsors
Ondokuz Mayıs University
Neon Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Having diffuse diabetic macular edema persisted at least 1 month * No intravitreal injection in last 3 months. * No retinal laser photocoagulation in last 6 months * Not have any other macular disease causing macular edema
Exclusion criteria
* Having ischemic macula * Intravitreal injection in last 3 months. * Retinal laser photocoagulation in last 6 months * Have any other macular disease causing macular edema
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Central Macular Thickness | one year (between May 2015 and May 2016) |
Outcome results
None listed